Literature DB >> 2008987

Lung function and bronchial reactivity in asthmatics during exposure to volatile organic compounds.

H Harving1, R Dahl, L Mølhave.   

Abstract

The purpose of the present study was to investigate whether vapors of organic solvents at low concentrations could exert an adverse effect in the lower airways. Under controlled conditions in a climate chamber, 11 persons with bronchial hyperreactivity to histamine and bronchial asthma were exposed for 90 min to a mixture of organic solvents at levels of zero, 2.5, and 25 mg/m3. During exposure to 25 mg/m3 a decrease in FEV1 to 90.7% of baseline value was measured. This was significantly different from the initial value (p less than 0.05), but not significantly different from the value found after sham exposure (FEV1, 97.4% of initial value). The decline in FEV1 during exposure to 25 mg/m3 was most pronounced in persons with high bronchial sensitivity. No changes were found in histamine reactivity after exposure, and no late reactions were registered. Ratings of discomfort showed different individual patterns ranging from no response to reactions towards both of the concentrations. The ratings indicated development of tolerance during exposure. Volatile organic compounds in concentrations found in both the work and the home environments may influence lung function and are probably of importance as bronchial irritants.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2008987     DOI: 10.1164/ajrccm/143.4_Pt_1.751

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  16 in total

1.  Pulmonary function and respiratory symptoms in a population of airport workers.

Authors:  W S Tunnicliffe; S P O'Hickey; T J Fletcher; J F Miles; P S Burge; J G Ayres
Journal:  Occup Environ Med       Date:  1999-02       Impact factor: 4.402

2.  Association of domestic exposure to volatile organic compounds with asthma in young children.

Authors:  K Rumchev; J Spickett; M Bulsara; M Phillips; S Stick
Journal:  Thorax       Date:  2004-09       Impact factor: 9.139

3.  (M)VOC and composting facilities. Part 1: (M)VOC emissions from municipal biowaste and plant refuse.

Authors:  Thomas Müller; Ralf Thissen; Silvia Braun; Wolfgang Dott; Guido Fischer
Journal:  Environ Sci Pollut Res Int       Date:  2004       Impact factor: 4.223

4.  Occupational exposure to water-based paints and self-reported asthma, lower airway symptoms, bronchial hyperresponsiveness, and lung function.

Authors:  G Wieslander; C Janson; D Norbäck; E Björnsson; G Stålenheim; C Edling
Journal:  Int Arch Occup Environ Health       Date:  1994       Impact factor: 3.015

5.  (M)VOC and composting facilities. Part 2: (M)VOC dispersal in the environment.

Authors:  Thomas Müller; Ralf Thissen; Silvia Braun; Wolfgang Dott; Guido Fischer
Journal:  Environ Sci Pollut Res Int       Date:  2004       Impact factor: 4.223

6.  Mortality and cancer incidence of aircraft maintenance workers exposed to trichloroethylene and other organic solvents and chemicals: extended follow up.

Authors:  A Blair; P Hartge; P A Stewart; M McAdams; J Lubin
Journal:  Occup Environ Med       Date:  1998-03       Impact factor: 4.402

7.  Asthmatic symptoms and volatile organic compounds, formaldehyde, and carbon dioxide in dwellings.

Authors:  D Norbäck; E Björnsson; C Janson; J Widström; G Boman
Journal:  Occup Environ Med       Date:  1995-06       Impact factor: 4.402

Review 8.  Hazardous air pollutants and asthma.

Authors:  George D Leikauf
Journal:  Environ Health Perspect       Date:  2002-08       Impact factor: 9.031

9.  Volatile organic compounds contribute to airway hyperresponsiveness.

Authors:  An-Soo Jang; Inseon-S Choi; Young-Il Koh; Choon-Sik Park
Journal:  Korean J Intern Med       Date:  2007-03       Impact factor: 2.884

Review 10.  Epidemiologic evidence for asthma and exposure to air toxics: linkages between occupational, indoor, and community air pollution research.

Authors:  Ralph J Delfino
Journal:  Environ Health Perspect       Date:  2002-08       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.